La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Xilio Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Xilio Therapeutics..

Xilio Therapeutics (NASDAQ:XLO) Azioni, Catena delle Opzioni

Xilio Therapeutics

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

Xilio Therapeutics Inc

Alphabet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) and the U.S. Department of Justice are set to present closing arguments on Monday in a trial to determine if Google&#8217;s advertising technology<a href="https://www.benzinga.com/government/regulations/24/11/42143421/staggering-google-breakup-proposal-from-doj-a-kitchen-sink-moment-alphabet-analyst"> constitutes an illegal monopoly.</a>
The Details: The DOJ alleges Google maintains a monopoly in "open-web display advertising" by dominating all aspects of the marketplace with a funnel of technologies that match online publishers to advertisers as well as controls the ad exchange market, which matches the buy side to the sell side.&nbsp;
"One monopoly is bad enough. But a trifecta of monopolies is what we have here," Justice Department lawyer Julia Tarver Wood said during her opening statement.
Read More: <a href="https://www.benzinga.com/general/social-media/24/11/42119493/rumble-eyes-buying-bitcoin-could-it-be-the-next-microstrategy">Rumble CEO Considers Bitcoin Investment, Engages Michael Saylor As Shares Rally</a>
Google says that the DOJ's case is focused on a narrow niche of digital advertising and that the company's market share of 25% has been decreasing as competition has increased in the space.&nbsp;
According to the AP, court documents show that Google argues the government's case "boil(s) down to the persistent complaints of a handful of Google's rivals and several mammoth publishers."
The case is being heard by U.S. District Judge Leonie Brinkema, in Alexandria, Virginia, who is expected to decide the case and issue a written ruling by the end of the year.&nbsp;
What Else: A District of Columbia judge, in a separate case, ruled in August that Google's search engine business does constitute a monopoly. The DOJ presented its proposed remedies last week, which included the requirement for Alphabet to divest Google Chrome, the internet&#8217;s leading browser with over 60% market share globally.
Other <a href="https://www.benzinga.com/government/regulations/24/11/42119020/alphabet-bleeds-over-120-billion-in-market-value-eyes-worst-day-in-10-months-after-doj-demands-google-chrome-sale#google_vignette">proposals included</a> forcing Google to share search data with competitors, and ending default search agreements, which make Google the automatic search engine on devices and web browsers like Apple&#8217;s Safari.
&#8220;Google&#8217;s unlawful behavior has deprived rivals not only of critical distribution channels but also distribution partners who could otherwise enable entry into these markets by competitors in new and innovative ways,&#8221; the DOJ said in a statement.
The judge is expected to deliver a final decision in that case next summer.&nbsp;
Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Alphabet shares are up 1.92% at $167.92 at the time of publication Monday. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/etfs/24/11/42044642/trump-appears-frustrated-as-elon-musk-chimes-in-on-treasury-secretary-adds-more-names-to-a-list-of-potential-picks">Trump Appears &#8216;Frustrated&#8217; As Elon Musk Chimes In On Treasury Secretary, Adds More Names To Short List&nbsp;</a></li>
</ul>
Image: Shutterstock

Large Cap

News

Legal

Movers

Tech

GOOG

GOOGL

Google, DOJ Present Closing Arguments In AdTech Trial Monday

RBC Capital analyst Gregory Renza maintains Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) with a Outperform and lowers the price target from $25 to $16.

Price Target

Analyst Ratings

CATX

RBC Capital Maintains Outperform on Perspective Therapeutics, Lowers Price Target to $16

WIIM

RNAZ

TransCode Therapeutics shares are trading lower after the company announced a 1-for-33 reverse stock split.

Wells Fargo analyst Roger Read maintains EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) with a Overweight and raises the price target from $42 to $52.

Wells Fargo Maintains Overweight on EQT, Raises Price Target to $52

Analog Devices's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NYSE">ADI</a>) short percent of float has fallen 21.05% since its last report. The company recently reported that it has 7.43 million shares sold short, which is 1.5% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.07 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Analog Devices Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732549520_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Analog Devices has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Analog Devices's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Analog Devices's peer group average for short interest as a percentage of float is 4.84%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into Analog Devices's Recent Short Interest

Old National's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONB#NYSE">ONB</a>) short percent of float has risen 7.32% since its last report. The company recently reported that it has 9.46 million shares sold short, which is 3.81% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.3 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Old National Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732549515_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Old National has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Old National's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Old National's peer group average for short interest as a percentage of float is 3.09%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Old National's Recent Short Interest

Time's running out. The Biden administration is in a mad dash to finalize billions in CHIPS Act deals before Trump takes office. With $39 billion in funding at stake, there's no room for delays.
The CHIPS Act, signed in 2022, was supposed to bring <a href="https://www.benzinga.com/markets/equities/24/10/41387939/chipmakers-rally-nvidia-smashes-records-on-tsmc-blowout-earnings-gold-hit-all-time-highs-whats-d">chip production</a> home. The goal? Secure supply chains and cut reliance on Taiwan for advanced semiconductors. It's a big deal for U.S. manufacturing. But there's a catch. While 90% of the money is allocated, most of it hasn't been locked down yet. Only two deals, worth $6.6 billion, are fully finalized, <a href="https://www.commerce.gov/news/press-releases/2024/11/biden-harris-administration-announces-chips-incentives-award-tsmc">according to the Commerce Department.</a>
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
</ul>
Commerce Secretary Gina Raimondo promised to allocate every dollar by the end of the year. But progress? It's been slow. And patience is wearing thin. "We are disappointed by how long and how slow the dispensing of funds has been," said Intel CEO Pat Gelsinger, as reported by Bloomberg. He's frustrated. The process has dragged on for over two years.
President Joe Biden's team is trying to speed things up. Last week, they announced<a href="https://www.benzinga.com/government/regulations/24/11/42011035/just-before-bidens-term-ends-taiwan-semiconductor-lands-6-6-billion-in-us-funding-to-build-advanced-chip-plants"> a $6.6 billion deal </a>with Taiwan's TSMC. At least $1 billion should roll out before the year ends. But there's still a lot left to sort out. Intel, the biggest potential recipient, is still negotiating terms to unlock its share.
President-elect Donald Trump, meanwhile, isn't a fan of the CHIPS Act. He's been vocal. He thinks tariffs are a better way to push companies to make chips here. On a podcast with Joe Rogan, he called tariffs the smarter move. His team might shift gears when he takes office. But here's the thing: once a CHIPS Act deal is finalized, it's tough to undo. They're legally binding unless companies don't hold up their end of the bargain.
Trending: This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a>
Analysts like Jeff Koch say Trump could slow things down, even if he doesn't scrap the CHIPS Act. "This had the ancillary benefit of pushing the Biden administration to cut through red tape and disburse CHIPS Act funds while still in power," Koch told Business Insider.
There's also pressure from the clock. January is fast approaching. Biden's team knows the window to finalize these agreements is closing. The next administration could stall or rewrite the rules, adding more uncertainty to a complicated process.
And it's not just about securing funding. There are benchmarks. <a href="https://www.benzinga.com/news/earnings/24/10/41654832/intel-likely-to-report-q3-loss-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Companies like Intel </a>need clear terms to access the money. Another layer of bureaucracy is slowing things down. For Biden, it's a race against time to solidify the vision of the CHIPS Act before Trump's team takes over.
The stakes are high. America needs these funds locked in to compete globally. Chips power everything from smartphones to cars, so falling behind isn't an option. All eyes are on whether Biden can pull this off in time. The pressure's on and there's no room for missteps.
Read Next:
<ul>
<li>Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest TODAY for just $0.26/share with a $1000 minimum.</a></li>
</ul>

Startups

'We Are Disappointed.' Intel CEO Criticizes Delays As Biden Pushes $6.6 Billion To TSMC

Zebra Technologies's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NYSE">ZBRA</a>) short percent of float has fallen 17.52% since its last report. The company recently reported that it has 511 thousand shares sold short, which is 1.13% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.07 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Zebra Technologies Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732549510_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Zebra Technologies has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Zebra Technologies's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Zebra Technologies's peer group average for short interest as a percentage of float is 6.77%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

ZBRA

Looking Into Zebra Technologies's Recent Short Interest

Diana Shipping shares are trading lower after the company reported worse-than-expected Q3 sales results.

IMUX

Immunic shares are trading higher after HC Wainwright initiated coverage on the stock with a Buy rating and announced a $10 price target.

Wells Fargo maintains Expand Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) with a Equal-Weight and raises the price target from $83 to $100.

Wells Fargo Maintains Equal-Weight on Expand Energy, Raises Price Target to $100

Palatin Technologies shares are trading higher after the company announced the completion of enrollment in its Phase 2 Study of PL8177.

Editor's Note: The headline has been corrected to accurately reflect the quoted material.
Elon Musk on Saturday shared a cryptic tweet on X, hinting at a significant turning point in human history.
What Happened: Musk&nbsp;responded to a post on X by Bojan Tunguz, which referred to an unspecified event as &#8220;one of the major inflection&nbsp;points of human history.&#8221; Musk&#8217;s reply was enigmatic, stating, &#8220;I knew if I brought&nbsp;a sink they would have&nbsp;to let that sink in.&nbsp;How could they not?&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I knew if I brought a sink they would have to let that sink in. How could they not? <a href="https://t.co/voEVBMC7Ht">https://t.co/voEVBMC7Ht</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1860199022121943545?ref_src=twsrc%5Etfw">November 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The Tesla and SpaceX CEO&#8217;s post on X has left his followers intrigued, as they attempt to decipher the meaning behind his cryptic words.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42152684/musk-tweet-sparks-dogecoin-surge-fuels-speculation-on-x-payments">Musk Tweet Sparks Dogecoin Surge, Fuels Speculation On X Payments</a>
Why It Matters: Musk is known for his cryptic tweets, which often lead to widespread speculation. His recent tweet, which suggests a significant turning point in human history, has sparked a flurry of theories among his followers.
While the exact meaning behind Musk&#8217;s tweet remains unclear, it underscores his reputation as a thought leader in the tech industry, known for pushing boundaries and challenging conventional thinking.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/42152586/judge-rejects-sec-bid-to-penalize-musk-over-missed-deposition">Judge Rejects SEC Bid to Penalize Musk Over Missed Deposition</a></li>
</ul>
Photo: Shutterstock

Social Media

'I Knew If I Brought A Sink': What Does Elon Musk's Cryptic Tweet Mean? (CORRECTED)

B of A Securities analyst Omar Dessouky maintains AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Buy and raises the price target from $252 to $375.

B of A Securities Maintains Buy on AppLovin, Raises Price Target to $375

Elon Musk recently set social media abuzz with a tweet featuring a clip from Netflix&#8217;s &#8220;Narcos,&#8221; where Pablo Escobar, portrayed by actor Wagner Moura, is seen smoking a joint. Musk captioned the post, &#8220;Actual footage of me after @realDonaldTrump won,&#8221; referring to <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">Donald Trump&#8217;s 2024 victory</a>. The tweet&#8217;s provocative nature, tying a drug kingpin character to a political celebration, triggered a range of reactions online.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Actual footage of me after <a href="https://twitter.com/realDonaldTrump?ref_src=twsrc%5Etfw">@realDonaldTrump</a> won <a href="https://t.co/PhPJjzaw0J">pic.twitter.com/PhPJjzaw0J</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1860475842800812347?ref_src=twsrc%5Etfw">November 24, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<h3 class="wp-block-heading">Musk's Cannabis Advocacy And Public Persona</h3>
Musk's selection of a cannabis-themed scene aligns with his public stance on marijuana and psychedelics. In 2018, Musk famously smoked a joint during a live appearance on &#8220;The Joe Rogan Experience,&#8221; sparking both cultural fascination and corporate scrutiny. The incident even prompted NASA to review SpaceX's workplace practices.
Beyond this, Musk has consistently supported the legalization of <a href="https://www.benzinga.com/cannabis">cannabis</a> and the therapeutic use of <a href="https://www.benzinga.com/topic/psychedelics">psychedelics</a>, recently describing them as "pretty helpful" for conditions like PTSD and depression. His tweet juxtaposes this advocacy with a tongue-in-cheek nod to cannabis culture, though some critics have questioned the appropriateness of invoking Escobar&#8217;s likeness in the context of drug reform.
<h3 class="wp-block-heading">Musk's Role In Trump's Reelection And Political Context</h3>
The tweet coincides with Musk's increasing prominence in U.S. politics. As co-leader of the Department of Government Efficiency (DOGE), a special initiative within President-elect Donald Trump's upcoming administration, Musk is tasked with identifying waste in federal operations and driving cost-cutting measures.
See also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41951578/trump-taps-cannabis-supporters-elon-musk-vivek-ramaswamy-to-slash-government-spending">Trump Taps Cannabis Supporters Elon Musk, Vivek Ramaswamy To Slash Government Spending</a>
The role cements Musk's alignment with Trump's deregulatory platform, but his cannabis-friendly public image contrasts sharply with conservative perspectives on drug policy.
<h3 class="wp-block-heading">Wagner Moura's Political Views And Social Media Irony</h3>
Wagner Moura, the Brazilian actor known for his portrayal of Escobar in &#8220;Narcos,&#8221; holds progressive political views that contrast with Musk's alignment with Trump. Moura has openly <a href="https://www.yahoo.com/entertainment/wagner-moura-chasing-truth-100000406.html?utm_source=chatgpt.com&amp;guccounter=1&amp;guce_referrer=aHR0cHM6Ly9jaGF0Z3B0LmNvbS8&amp;guce_referrer_sig=AQAAAHyPGwAKPhq_ebbbAr72fKnwcPnvJS6EpQAlbqiXcPZejVhUfydhaxYD39x4-d1Xi4IZ9CYMdVNt30qS4HKVbbOP2T71GtilDmAimDnHraRNLm8zAuS3LxtiLjwBvSDS9Veg3PKX0XNT33KTYuXeq4qsqFCIZYHrN8nkqE3v-2vh">supported</a> leftist causes in Brazil and has been an outspoken critic of authoritarianism. While he has not directly criticized Trump on record, his advocacy for democratic values and opposition to leaders like Brazil's former president Jair Bolsonaro suggest ideological differences with Trump's approach.
This clash between Moura and Musk was not lost on social media. One Twitter user noted, "This actor is Brazilian. He hates Donald Trump and loves Fidel Castro," while another added, "This actor is Brazilian, liberal, and deeply hates you, Elon." Moura has not publicly commented on the incident, but the online reactions pointed out the irony of Musk's use of the clip
Photo by <a href="https://commons.wikimedia.org/wiki/User:Dmoberhaus">Daniel Oberhaus</a> via <a href="https://commons.wikimedia.org/wiki/File:Elon_Musk_at_a_Press_Conference.jpg">Wikimedia Commons</a>, edited by Benzinga

Cannabis

Politics

Did Elon Musk Really Use A Meme Of Pablo Escobar Smoking Weed To Celebrate Trump's Election Victory? What Does It Even Mean?

QNTM

Quantum BioPharma shares are trading higher after the company announced legal teams have been assembled to pursue the recovery of all losses and damages.

RBC Capital analyst Christopher Dendrinos maintains GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) with a Outperform and raises the price target from $285 to $376.

RBC Capital Maintains Outperform on GE Vernova, Raises Price Target to $376

UPXI

Upexi shares are trading lower. The company filed litigation in Nevada in determining manipulation of fractional share roundups during its reverse stock split.

JMP Securities analyst Andrew Boone maintains Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) with a Market Outperform and raises the price target from $118 to $160.

RDDT

JMP Securities Maintains Market Outperform on Reddit, Raises Price Target to $160

Vast Renewables Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) shares traded higher after the company signed <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42161696/vast-receives-30m-from-australian-renewable-energy-agency-for-green-technology-to-decarbonise-aust" rel="noreferrer noopener">an updated funding agreement</a>.
The agreement will give access up to $30 million of its $65 million grant from the Australian Renewable Energy Agency.
The funding will support Vast&#8217;s green technology manufacturing and project development, enabling the deployment of its next-generation concentrated solar thermal power (CSP) solution to provide clean, dispatchable power and heat.
Vast has developed next-generation proprietary CSP technology, offering superior performance at lower cost and risk.
The company has a global project pipeline aimed at decarbonizing electricity generation and powering green methanol and sustainable aviation fuel production.
Proven at its pilot project in New South Wales, Vast&#8217;s technology is set for utility-scale deployment at Vast Solar 1 (VS1), a 30MW power plant with 8 hours of storage in South Australia&#8217;s Port Augusta Green Energy Hub.
The Port Augusta CSP project will generate clean, dispatchable electricity for the National Electricity Market and power Solar Methanol 1 (SM1), a world-first green methanol production facility.
Vast&#8217;s Australian-made CSP technology, produced at its Queensland facility, will benefit from $30 million in funding from ARENA.
This will support the scaling of manufacturing for VS1 and future projects, as well as final development activities ahead of the Final Investment Decision in early 2025.
The funding is expected to create green manufacturing, construction, and long-term operations jobs.
Construction of VS1 is expected to start in the second quarter of 2025, with capital expenditures estimated between A$360 million and A$390 million.
CEO Craig Wood emphasized that the Australian Government support positions Vast to lead a domestic CSP industry and expand its global project pipeline.
Price Action: VSTE shares are up 30.4% at $2.151 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42165679" target="_blank" rel="noreferrer noopener">Nio Analyst Sees Tougher Path To Profitability, Downgrades EV Maker To Sell: What You Need To Know</a></li>
</ul>
Image via Unsplash.

Equities

Small Cap

VSTE

Vast Renewables Powers Up: $30M Funding Fuels Australia's Next-Gen Solar And Methanol Breakthrough

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Xilio Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/xlo-stock-quote/">XLO</a>) just reported results for the first quarter of 2024.<ul><li>Xilio Therapeutics reported earnings per share of -59 cents. This was below the analyst estimate for EPS of -11 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/xlo-stock-earnings-xilio-therapeutics-for-q1-of-2024/">XLO Stock Earnings: Xilio Therapeutics Misses EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

XLO Stock Earnings: Xilio Therapeutics Misses EPS for Q1 2024

Xilio Therapeutics (XLO) has provided an update. Xilio Therapeutics, Inc. has expanded its Board of Directors to nine members, welcoming James Shan...

Xilio Therapeutics Enhances Board with Two New Directors

Xilio Therapeutics GAAP EPS of -$0.24, revenue of $2.4M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Xilio Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/xlo-stock-quote/">XLO</a>) just reported results for the second quarter of 2024.<ul><li>Xilio Therapeutics reported earnings per share of -24 cents. This was below the analyst estimate for EPS of -23 cents.</li><li>The company reported revenue of $2.36 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/xlo-stock-earnings-xilio-therapeutics-for-q2-of-2024/">XLO Stock Earnings: Xilio Therapeutics Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

XLO Stock Earnings: Xilio Therapeutics Misses EPS for Q2 2024

TD Cowen analyst Marc Frahm maintained a Buy rating on Xilio Therapeutics (XLO – Research Report) yesterday. The company's shares closed yesterday ...

TD Cowen Remains a Buy on Xilio Therapeutics (XLO)

Xilio Therapeutics ( ($XLO) ) has shared an announcement. Xilio Therapeutics announced significant progress in its pipeline and financial updates f...

Xilio Therapeutics Advances Cancer Drug and Financial Outlook

TD Cowen analyst Marc Frahm maintained a Buy rating on Xilio Therapeutics (XLO – Research Report) today. The company's shares closed today at $1.04...

TD Cowen Keeps Their Buy Rating on Xilio Therapeutics (XLO)

Xilio Therapeutics Inc ( ($XLO) ) has released its Q3 earnings. Here is a breakdown of the information Xilio Therapeutics Inc presented to its inve...

Xilio Therapeutics Reports Q3 2024 Progress and Financials

Xilio Therapeutics reports Q3 results

Morgan Stanley analyst Michael Ulz has maintained their bullish stance on XLO stock, giving a Buy rating yesterday. Michael Ulz has given his Buy r...

Promising Pipeline and Financial Stability Drive Buy Rating for Xilio Therapeutics

Earnings

Press Releases

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results

Management

Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results

Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Markets

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Health Care

Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results

Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors

Comments

Xilio Therapeutics

Xilio Therapeutics (XLO) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO